We are a company that researches, develops, manufactures, and sells glycoconjugates, such as glycoproteins and glycopeptides. The development of ADCs using glycan linkers is progressing in the pharmaceutical industry, and we are capable of conducting basic research and contract-based research on these products as well as supplying large quantities of API raw materials. We are also conducting new research and development using glycans, including in mRNA vaccines and other macromolecular LNPs. Our in-house glycosylated somatostatin is currently undergoing clinical trials (Phase 2a), and we plan to out-license the technology in the future.
A startup developing allogeneic T-cell therapies from pluripotent stem cells to provide novel treatments for advanced and recurrent cancers and immune-related diseases. Aiming to deliver the potential for a cure to diseases that were previously difficult to treat.
We manufacture and sell rehabilitation devices using virtual reality that provide measurements useful for diagnosis and treatment, or that are used to evaluate task achievement levels.
A startup developing artificial red blood cells coated with a lipid bilayer. These cells possess oxygen-carrying capacity equivalent to red blood cells and enable long-term storage, aiming to revolutionize transfusion medicine through stable blood transfusions in veterinary medicine and future practical application in human healthcare.
Our mission is to safeguard the health of people worldwide. We are an Osaka University-spun-off healthcare startup in the healthcare/preventive medicine field, developing and providing the “Blood Vessel Beauty” scope—which observes capillary blood flow from the fingertip without blood sampling—along with the capillary image analysis software ‘CAS’ and the cloud-based evaluation system “CAS-Rating.” We research the relationship between capillary data and health/disease risks, aiming to implement new health indicators and preventive medical services in society.
